Library

Notes: Abstract: We examined the effects of an interruption of dopamine neurotransmission, by either dopamine receptor blockade or degeneration of dopamine neurons by 6-hydroxydopamine, on the levels of D2 receptor mRNAs. In addition, we evaluated by the polymerase chain reaction (PCR) the relative abundance of the two D2 receptor isoform mRNAs generated by alternative splicing. Daily injections of 4 mg/kg of haloperidol to rats elicited in striatum a rapid and progressive increase in D2 receptor mRNA levels, which reached 70% after a 15-day treatment. By contrast, there was no apparent change in D2 receptor mRNA levels in cerebral cortex and pons-medulla, in spite of an increased density of D2 receptor in the former tissue. Using the PCR with primers flanking the alternative exon, we observed that the relative proportion of the shorter receptor isoform (D2s) mRNA was slightly but significantly enhanced in cerebral cortex (17%) and pons-medulla (18%) after a 15-day haloperidol treatment. Unilateral degeneration of dopamine neurons induced by local injection of 6-hydroxydopamine resulted in a marked decrease in levels of total D2 receptor mRNAs in substantia nigra (—79%) and ventral tegmental (—63%) area, two cell body areas. In the substantia nigra, the longer isoform (D2l) mRNA was significantly more decreased in content than the D2s isoform mRNA, so that there was a large enhancement in the relative abundance of the latter (81%). In contrast, the lesion did not result in any significant change in levels of total D2 receptor mRNAs in striatum, but the relative proportion of D2s receptor mRNA tended to decrease—although nonsignificantly—as a result of a tendency of the D2l receptor mRNA abundance to rise. The present study establishes that two distinct processes of D2 receptor gene expression accompany and may contribute to the hypersensitivity known to develop at D2 receptors following either their chronic blockade by neuroleptics or dopamine denervation.

Notes: Abstract: The serotonin 5-HT3-A receptor (5-HT3R-A) mRNA has been shown recently to be expressed as two forms (5-HT3R-AL and 5-HT3R-AS) varying by the presence or the absence of a sequence of 18 bases in the region corresponding to the second cytoplasmic domain of the receptor, and generated by alternative splicing at the level of the 3′ acceptor site of exon 9. As the long form of the receptor exhibits a potential phosphorylation site that is disrupted by the alternative splicing, the hypothesis of functional identity and stochastic expression of these two variants was questioned. In the present study, we used quantitative reverse transcriptase-polymerase chain reaction to examine the possible influence of culture conditions on the expression and the alternative splicing of 5-HT3R-A mRNA in NG108-15 clonal cells. Cell differentiation induced by dibutyryl cyclic AMP or theophyllin plus prostaglandin E1 in the presence of 10% serum reduced by threefold the expression of total 5-HT3R-A mRNA, and favored the short form of the message as the ratio S/L (5-HT3R-AS mRNA/5-HT3R-AL mRNA) shifted from 2.23 to 7.33 after 9 days of treatment. Culture with 0.3% serum (instead of 10%) lowered by 10-fold the level of expression of total 5-HT3R-A mRNA, but only slightly reduced the S/L ratio. However, this ratio fell to 0.06 in the presence of 0.3% serum plus 10 ng/ml basic fibroblast growth factor. These results demonstrate that external factors can influence the differential expression of the two variants of the 5-HT3R-A in NG108-15 cells. Appropriate culture conditions for the almost exclusive expression of 5-HT3R-AS mRNA or 5-HT3R-AL mRNA in NG108-15 cells should allow the identification of possible differences in the respective functional properties of each of these two forms of the native 5-HT3 receptor.

Notes: Using in situ hybridization histochemistry in rat nucleus accumbens, we show that the dopamine D3 receptor mRNA is expressed in the ventromedial part of the shell subdivision, where its gross distribution matches that of neurotensin mRNA. In addition, hybridization studies at the cellullar level show that a large fraction of the neurotensin neurons co-express the D3 receptor mRNA in this restricted area. In contrast, the dopamine D2 receptor mRNA is expressed mainly in the core and marginally in the shell, at the level of the cone. In rats treated by haloperidol and sulpiride, two D2-like receptor antagonists, but not by SCH 23390, a D1-like receptor antagonist, proneurotensin mRNA was increased in the D2 receptor mRNA-rich areas but decreased in the D3 receptor mRNA-rich areas. This suggests that the D2 and D3 receptors control neurotensin mRNA expression negatively and positively, respectively.

Notes: By taking up serotonin (5-hydroxytryptamine, 5-HT) released in the extracellular space, the 5-HT transporter (5-HTT) regulates central 5-HT neurotransmission. Possible adaptive changes in 5-HT neurotransmission in knock-out mice that do not express the 5-HT transporter were investigated with special focus on 5-HT1A and 5-HT1B receptors. Specific labelling with radioligands and antibodies, and competitive RT-PCR, showed that 5-HT1A receptor protein and mRNA levels were significantly decreased in the dorsal raphe nucleus (DRN), increased in the hippocampus and unchanged in other forebrain areas of 5-HTT–/– vs. 5-HTT+/+ mice. Such regional differences also concerned 5-HT1B receptors because a decrease in their density was found in the substantia nigra (−30%) but not the globus pallidus of mutant mice. Intermediate changes were noted in 5-HTT+/– mice compared with 5-HTT+/+ and 5-HTT–/– animals. Quantification of [35S]GTP-γ-S binding evoked by potent 5-HT1 receptor agonists confirmed such changes as a decrease in this parameter was noted in the DRN (−66%) and the substantia nigra (−30%) but not other brain areas in 5-HTT–/– vs. 5-HTT+/+ mice. As expected from actions mediated by functional 5-HT1A and 5-HT1B autoreceptors, a decrease in brain 5-HT turnover rate after i.p. administration of ipsapirone (a 5-HT1A agonist), and an increased 5-HT outflow in the substantia nigra upon local application of GR 127935 (a 5-HT1B/1D antagonist) were observed in 5-HTT+/+ mice. Such effects were not detected in 5-HTT–/– mice, further confirming the occurrence of marked alterations of 5-HT1A and 5-HT1B autoreceptors in these animals.

Notes: [Auszug] The presence of opiate receptors on noradrenergic nerve terminals was investigated by measuring 3H-naloxone binding in brain regions receiving noradrenergic inputs, after chemical destruction of noradrenergic cell bodies. For 15-40 d after the slow unilateral infusion of 6-hydroxydopamine (6-OHDA) ...

Notes: Summary Dopamine receptors subtypes were studied in homogenates from rat brain areas, mainly the corpus striatum, using the two highly selective ligands 3H-apomorphine and 3H-domperidone. The clearly biphasic inhibition of the specific binding of these two ligands by some agents allowed us to define four distinct classes of binding site. 3H-apomorphine labels two classes of site displaying a large difference in affinity for domperidone, i.e. class I sites well recognized (IC50=5 nM) and class II sites poorly recognized (IC50=10 μM). 3H-domperidone also labels two distinet classes of site displaying a large difference in affinity for apomorphine and dopamine, i.e. class III sites well recognized by these agents (IC50=5 and 35 nM, respectively) and class IV sites poorly recognized (IC50=790 nM and 14 μM, respectively). The two classes I and III represent a single pharmacological class of dopaminergic receptors (labelled by either 3H-apomorphine or 3H-domperidone) as indicated by 1) their almost identical pharmacological specificities (high correlation between K d or K i values for a variety of dopaminergic agonists and antagonists); 2) their similar capacity in striatum as well as in other brain regions; 3) the identical decrease in capacity following kainate lesions; 4) their similar sensitivity to GTP and thermal denaturation. Because the pharmacological specificity of these sites excludes the possibility that they represent the recognition sites of the dopamine-sensitive adenylate cyclase, i.e. D-1 receptors, we propose to term them D-2 receptors. Class II and IV sites also differ from D-1 receptors as shown by drug specificity and the effect of kainate. We propose to term class II sites D-3 receptors and class IV sites D-4 receptors. D-2 receptors are characterised by a high affinity for both dopamine receptor agonists and antagonists (K i and K d values in the nM range). They are localised post-synaptically to dopaminergic terminals in the striatum as indicated by 1) their decreased number (−60%) following kainate lesions of intrinsic neurones, and 2) their increased number (+40%) after 6-OHDA-induced degeneration of dopaminergic neurones. The capacity of D-2 receptors is decreased by 80% in the presence of 25 μM GTP. The binding of ligands to D-2 receptors preicubated at 45°C decreases with a half-life of 10 min. D-2 receptors may mediate behavioral actions of apomorphine in low dosage which are easily antagonised by neuroleptics. D-3 receptors appear to be, at least in part, autoreceptors: their number decreases in striatum after 6-OHDA lesions (−30%) and is not modified following kainate lesions. They are characterised by a high affinity (K i in the nM range) for dopaminergic agonists (except for bromocriptine) contrasting with a rather low affinity for antagonists. The pharmacologically homogeneous class of D-3 receptor appears heterogeneous regarding both localisation and regulation by GTP. D-4 receptors are partly localised on intrastriatal neurones (−17% after kainate lesions, +17% following 6-OHDA lesions). However, the small change after kainate-induced lesions suggests that a significant fraction of D-4 receptors is localised on terminals from extrinsic neurones. D-4 receptors are characterised by a high affinity for dopamine receptor antagonists (K i in the nM range) contrasting with a relatively low affinity for agonists. The number of D-4 receptors increases after either GTP or heat denaturation, a change which probably corresponds to the decrease in D-2 receptors. D-4 receptors may mediate typical behavioral actions of apomorphine in moderate dosage.